Last reviewed · How we verify
CHOP21
CHOP21 is a chemotherapy regimen used to treat various types of cancer.
CHOP21 is a chemotherapy regimen used to treat various types of cancer. Used for Non-Hodgkin lymphoma, Other types of blood cancers.
At a glance
| Generic name | CHOP21 |
|---|---|
| Also known as | CHOP 21 arm |
| Sponsor | University Hospital, Grenoble |
| Drug class | chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CHOP21 is a combination of chemotherapy drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone, which work together to kill cancer cells. This regimen is typically used to treat non-Hodgkin lymphoma and other types of blood cancers.
Approved indications
- Non-Hodgkin lymphoma
- Other types of blood cancers
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
Key clinical trials
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (PHASE1)
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (PHASE3)
- Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance (PHASE2)
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma (PHASE3)
- Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma (PHASE3)
- A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL (PHASE3)
- An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma (PHASE4)
- Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHOP21 CI brief — competitive landscape report
- CHOP21 updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI